$6.95
0.0350.51%
Dern. MÀJ: Oct 14, 11:27 AM
$6.90
-0.01-0.14%
Emergent BioSolutions (EBS) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Q3 (2026) a publié ses dernières prévisions le $110M - $130M pour Emergent BioSolutions {{epsDirection}}. La société a prévu un chiffre d'affaires compris entre {{epsPriorRange}} et {{revenueDirection}} pour la période.
Par rapport aux prévisions précédentes, {{newestDate}} {{directionSummary}} ses prévisions de chiffre d'affaires ont été revues à la baisse, passant d'une fourchette précédente de undefined à undefined.
undefined a publié undefined mises à jour de ses recommandations entre undefined et undefined. undefined
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.11 | $-0.25 | $0.32 | $-0.03 |
| Actual | $0.60 | $0.21 | $-0.43 | $1.06 |
| Surprise | +445.5% | +184.0% | -234.4% | +3633.3% |
| Revenue | ||||
| Estimate | $179.4M | $157.4M | $216.5M | $198.6M |
| Actual | $234.3M | $156.1M | $148.7M | $231.1M |
| Surprise | +30.6% | -0.83% | -31.3% | +16.4% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.40 | $-0.10 | $-0.53 | $0.23 |
| Revenue | ||||
| Consensus | $123.2M | $142.7M | — | — |
| Trimestre Fiscal | Date de Déclaration | BPA Réel | BPA Estimé | Surprendre % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $0.60 | $0.11 | 445.5 % |
| Q1 | Apr 30, 2026 | $0.21 | $-0.25 | 184.0 % |
| Q4 | Feb 26, 2026 | $-0.43 | $0.32 | -234.4 % |
| Q3 | Oct 29, 2025 | $1.06 | $-0.03 | 3633.3 % |
| Trimestre Fiscal | Date de Déclaration | Revenu Réel | Revenu Estimé | Surprendre % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $234.30M | $179.40M | 30.6 % |
| Q1 | Apr 30, 2026 | $156.10M | $157.40M | -0.83 % |
| Q4 | Feb 26, 2026 | $148.70M | $216.50M | -31.3 % |
| Q3 | Oct 29, 2025 | $231.10M | $198.60M | 16.4 % |